Seung Yeon Ha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Seung Yeon Ha has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Jeong‐Heum Baek
Department of Surgery Gil Medical Center Gachon University, School of Medicine Incheon Korea
1 shared publicationJung Nam Lee
Department of Surgery Gil Medical Center Gachon University, School of Medicine Incheon Korea
1 shared publicationTae‐Hoon Lee
Department of Surgery Gil Medical Center Gachon University, School of Medicine Incheon Korea
1 shared publicationWon‐Suk Lee
Department of Surgery, Gil Medical Center, Gachon University, School of Medicine, Incheon, Korea
1 shared publicationYeon Ho Park
Department of Surgery Gil Medical Center Gachon University, School of Medicine Incheon Korea
1 shared publication
Latest Publications
- Open Access
- 25 March 2014
- Published by Wiley in Cancer Medicine
- Vol. 3 (3) , 674-680
Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases
The aim of this study was to compare human epidermal growth factor 2 (HER2) status in primary colorectal cancer and paired liver or lung metastasis. Gene amplification of HER2 has been intensively evaluated in contemporary oncology, especially in breast and stomach cancer. The knowledge of HER2 status in primary and metastatic sites may be of potential value for therapeutic decision making in metastatic colon cancer. The HER2 status was assessed by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in 94 colorectal cancer with corresponding liver or lung metastases. HER2 amplification was present in 19 of the 188 (10.1%) of both primary and metastases combined. Four (4.6%) patients showed HER2 amplification in the metastasis and 10 (10.6%) patients showed HER2 amplification in the primary tumor. In 14 cases (14.8%), the HER2 status of the primary lesions was different from that of the associated metastases. The presence of HER2 overexpression in KRAS mutant colon cancer was found in 5.3%. No relationship was found between HER2 expression and KRAS status (P = 0.486). The evidence of HER2 positive metastatic lesion and primary colorectal cancer suggest that HER2 assessment might be considered in selected cases when this may help change the therapeutic decision.
- 25 March 2014
- Published by Wiley in Cancer Medicine
- Vol. 3 (3) , 674-680
Open AccessComparison of HER2 expression between primary colorectal cancer and their corresponding metastases
The aim of this study was to compare human epidermal growth factor 2 (HER2) status in primary colorectal cancer and paired liver or lung metastasis. Gene amplification of HER2 has been intensively evaluated in contemporary oncology, especially in breast and stomach cancer. The knowledge of HER2 status in primary and metastatic sites may be of potential value for therapeutic decision making in metastatic colon cancer. The HER2 status was assessed by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in 94 colorectal cancer with corresponding liver or lung metastases. HER2 amplification was present in 19 of the 188 (10.1%) of both primary and metastases combined. Four (4.6%) patients showed HER2 amplification in the metastasis and 10 (10.6%) patients showed HER2 amplification in the primary tumor. In 14 cases (14.8%), the HER2 status of the primary lesions was different from that of the associated metastases. The presence of HER2 overexpression in KRAS mutant colon cancer was found in 5.3%. No relationship was found between HER2 expression and KRAS status (P = 0.486). The evidence of HER2 positive metastatic lesion and primary colorectal cancer suggest that HER2 assessment might be considered in selected cases when this may help change the therapeutic decision.